Web Images Videos Maps News Shopping Gmail more »
Sign in
Scholar Home  
  Advanced Scholar Search
Scholar Preferences
Scholar Results 1 - 9 of 9 citing Stewart: Predicted biological activity of intravitreal VEGF Trap. (0.07 sec) 

Anti-VEGF Therapeutic Approaches for Diabetic Macular Edema


RN Khurana, DV Do, QD Nguyen - International Ophthalmology Clinics, 2009 - journals.lww.com
Diabetic retinopathy is the leading cause of blindness in people of working
age.1 Diabetic macular edema (DME) is the most common cause of moderate vision
loss among this population.2,3 The Early Treatment Diabetic Retinopathy ...
Related articles - All 2 versions

Vascular Endothelial Growth Factors and Their Inhibitors in Ocular Neovascular Disorders

- jovr.ir [PDF] 
M Homayouni - Journal of Ophthalmic & Vision Research, 2009 - jovr.ir
The introduction of pharmacotherapy has been one of the most important advances
in the management of retinal disorders. Age-related macular degeneration (AMD)
was once considered as an irrepressible disease leading to permanent ...
Related articles - View as HTML - All 7 versions

[PDF] exudative Age-Related Macular Degeneration: current Therapies and potential Treatments


PA Quiram, Y Song - la-press.com
This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://www.creativecommons.org/licenses/by/2.0)
which permits unrestricted use, distribution and reproduction provided the ...
Related articles - View as HTML - All 2 versions

Intravitreal Injection of Therapeutic Agents


GA PEYMAN, EM LAD, DM MOSHFEGHI - Retina, 2009 - journals.lww.com
Intravitreal injection (IVI) was initially performed for treatment of retinal
detachment (RD) and vit- reous hemorrhage. In 1895, Deutschmann1 injected
transplanted rabbit vitreous, and Ohm2 injected air in the vitreous cavity ...
Related articles - All 5 versions

Safety Implications of Vascular Endothelial Growth Factor Blockade for Subjects Receiving …


K Csaky, DV Do - American Journal of Ophthalmology, 2009 - Elsevier
Several prospective, randomized clinical trials have demonstrated that
intravitreal anti-VEGF therapies generally are well tolerated. However, within
these trials, there is some circumstantial evidence that links systemic ...
Related articles - All 2 versions

Vascular endothelial growth factor Trap-Eye for diabetic macular oedema

- duanessolution.com
PK Kaiser - British Journal of Ophthalmology, 2009 - bjo.bmj.com
Diabetic macular oedema (DMO) is the leading cause of visual loss in
working-aged Americans, and as such successful treatment is of major public
health importance. The gold standard is laser photocoagulation based on the ...
Related articles - All 7 versions

Current Molecular Understanding and Future Treatment Strategies for Pathologic Ocular …


MJ Tolentino - Current Molecular Medicine, 2009 - ingentaconnect.com
Center for Retina and Macular Disease, 250 Avenue K SW, Winter Haven, Fl 33880,
USA Abstract: The leading cause of blindness in the developed world results from
several disorders that have pathologic ocular neovascularization as the ...
Related articles

Strategies for Inhibiting Vascular Endothelial Growth Factor


PK KAISER - Retina, 2009 - journals.lww.com
Clinical trials increasingly support the premise that inhibition of vascular
endothelial growth factor is a viable but insufficient target for long-term
control of age-related macular degeneration (AMD). Additional biologic ...
Related articles - All 3 versions

Emerging drugs for diabetic retinopathy


Q Mohamed, TY Wong - Expert Opinion on Emerging Drugs, 2008 - Informa Pharma Science
Diabetic retinopathy (DR) is prevalent even among “well controlled”
diabetics, and remains the commonest cause of visual loss in working age adults.
Current evidence based treatments, including intensive glycemic and ...
Related articles - All 6 versions


 


Go to Google Home - About Google - About Google Scholar

©2009 Google